Becton, Dickinson and Company (NYSE:BDX) Issues FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of 12.350-12.650 for the period, compared to the consensus EPS estimate of 14.810. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BDX shares. Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Jefferies Financial Group upped their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Five investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $213.36.

Becton, Dickinson and Company Stock Performance

BDX opened at $210.45 on Monday. The firm’s 50-day moving average price is $199.83 and its 200-day moving average price is $192.36. The company has a market cap of $59.96 billion, a P/E ratio of 36.10, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $235.34. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.09. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 2,463 shares of company stock worth $501,530 in the last three months. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Quadcap Wealth Management LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter worth about $341,000. Measured Wealth Private Client Group LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $124,000. Boothbay Fund Management LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $332,000. Finally, Dauntless Investment Group LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $348,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.